ARGX Stock Analysis: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$802.70
-10.11 (-1.24%)
▼
5d:
-0.6%
30d:
-3.1%
90d:
-3.82%
BUY
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ARGX shows positive signals but monitor for confirmation. Market pricing in 3.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ARGX shows positive signals but monitor for confirmation. Market pricing in 3.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1522.26
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$945.20
15.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $802.70, which is considered fair relative to its 30-day fair value range of $775.91 to $821.78. From a valuation perspective, the stock is trading at a discount (Forward PE: 25.7) compared to its historical average (28.6). Remarkably, the market is currently pricing in an annual earnings decline of 3.5% over the next few years. This pessimistic expectation contrasts with the company's recent 114.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ARGX is in a downtrend. Immediate support is located at $775.02, while resistance sits at $840.67.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1032.52 (+28.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARGX is in a downtrend. Immediate support is located at $775.02, while resistance sits at $840.67.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1032.52 (+28.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$775.91 -
$821.78
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.6% below Wall St target ($1032.52)
Trading Range Analysis
30-Day Trading Range
$775.91 -
$821.78
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$775.02
Resistance Level
$840.67
Current Trend
Downtrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
25.67
Wall Street Target
$1032.52
(+28.6%)
Revenue Growth (YoY)
62.6%
Earnings Growth (YoY)
114.0%
Profit Margin
31.4%
Valuation Discount vs History
-3.5% cheaper
PE vs Historical
25.7 vs 28.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.5%
(market-implied from PE analysis)
1-Year Target
$774.61
(-4%)
2-Year Target
$747.49
(-7%)
3-Year Target
$721.33
(-10%)
3-Yr Target (if PE normalizes)
(PE: 26→29)
$803.62
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 25.7, Growth: 42.4%)
$2316.35
(+189%)
Base:
(SPY PE: 22.0, Growth: 42.4%)
$1988.68
(+148%)
Bear:
(PE: 18.7, Growth: 42.4%)
$1690.38
(+111%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (26x PE) as earnings recover.
Trailing PE: 36.08 | Current EPS (TTM): $22.54
Bull Case
$1241.03
(+55%)
Analyst growth 38.7%, PE expands to 39.7
Base Case
$1128.21
(+41%)
Market implied 38.7%, PE stable at 36.1
Bear Case
$553.03
(-31%)
Severe decline -20.0%, PE contracts to 30.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 25.7 to 28.6
Stabilization Target:
$894.27
(+11.4%)
PE Expansion Potential:
+11.4%
Share & Embed Analysis
Last updated: May 14, 2026 10:46 AM ET
Data refreshes hourly during market hours. Next update: 11:46 AM
Data refreshes hourly during market hours. Next update: 11:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 64 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
